APA (7th ed.) Citation

Huang, Y., Wen, G., Lu, Y., Wen, J., Ji, Y., Xing, X., . . . Yuan, H. (2017). CYP3A41G and CYP3A53 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation. International journal of clinical pharmacology and therapeutics, 55(2), 109-118. https://doi.org/10.5414/CP202559

Chicago Style (17th ed.) Citation

Huang, Yun, Gaiyan Wen, Yao Lu, Jia Wen, Ying Ji, Xiaowei Xing, Ying Li, Juan Wen, and Hong Yuan. "CYP3A41G and CYP3A53 Genetic Polymorphisms Alter the Antihypertensive Efficacy of Amlodipine in Patients with Hypertension Following Renal Transplantation." International Journal of Clinical Pharmacology and Therapeutics 55, no. 2 (2017): 109-118. https://doi.org/10.5414/CP202559.

MLA (9th ed.) Citation

Huang, Yun, et al. "CYP3A41G and CYP3A53 Genetic Polymorphisms Alter the Antihypertensive Efficacy of Amlodipine in Patients with Hypertension Following Renal Transplantation." International Journal of Clinical Pharmacology and Therapeutics, vol. 55, no. 2, 2017, pp. 109-118, https://doi.org/10.5414/CP202559.